Myeloid neoplasms with germline DDX41 mutation.

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Germline and somatic DDX41 mutations are increasingly recognized in familial myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).
• DDX41 mutations often present as frameshift variants, suggesting a tumor suppressor role, with a common somatic missense mutation also identified.

Purpose of the Study:

• To review the molecular, clinical, and biological implications of DDX41 mutations in myeloid malignancies.
• To explore potential therapeutic strategies targeting pathways affected by DDX41 dysfunction.

Main Methods:

• Literature review of studies on DDX41 mutations in myeloid cancers.
• Analysis of clinical presentations and functional consequences of DDX41 alterations.

Main Results:

• DDX41 mutations predispose individuals to high-risk MDS/AML at a similar age to sporadic cases, complicating familial diagnosis.
• Functional studies reveal DDX41's role in mRNA splicing, innate immunity, and rRNA processing, with mutations causing aberrations in these pathways.

Conclusions:

• Understanding the multifaceted roles of DDX41 in tumorigenesis provides a basis for developing targeted therapies.
• Pathway-specific inhibitors represent a promising therapeutic avenue for patients with DDX41-mutated myeloid malignancies.